TheraRadar
Data updated: May 26, 2026

CYKLX (articaine hydrochloride)

Other Approved 2025-08-15

CYKLX is a combination medication used to provide local numbing during both simple and complex dental procedures. It helps patients by blocking pain signals in the specific area where the dentist is working. This treatment is used for adults and children who are at least four years of age.

Source: FDA Label • THEA PHARMA

How CYKLX Works

This drug works by blocking the generation and conduction of nerve impulses, which

1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Discontinued
First Approved
2025-08-15
Patent Cliff
2039

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: ARTICAINE HYDROCHLORIDE

CYKLX Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Aug 2025 ORIGINAL
Update · Type 3 - New Dosage Form and Type 4 - New Combination

What CYKLX Treats

1 FDA approvals

Originally approved for its first indication in 2025 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CYKLX FDA Label Details

Indications & Usage

FDA Label (PDF)

Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older .

CYKLX Patents & Exclusivity

Latest Patent: Mar 2039
Exclusivity: Aug 2028

Patents (3 active)

US12403126 Expires Mar 27, 2039
US11826347 Expires Mar 27, 2039
US11096922 Expires Mar 27, 2039

Exclusivity

NP Until Aug 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for CYKLX

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2039
  • 3 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.